

## Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



## **Minutes**

Regular Meeting & Administrative Hearing

Location:

Wednesday, May 29, 2019 at 1:00 p.m.

Thursday, May 30, 2019 at 8:30 a.m.

Louisiana Board of Pharmacy 3388 Brentwood Drive Baton Rouge, Louisiana 70809-1700

## **Table of Contents**

Agenda Item	No. <u>Description</u> P	age No
Wednesday,	May 29, 2019	
1.	Call to Order	04
2.	Invocation & Pledge of Allegiance	04
3.	Quorum Call	04
4.	Call for Additional Agenda Items & Adoption of Agenda	05
5.	Consideration of Minutes from Previous Meeting	05
6.	Report on Action Items	05
7.	Confirmation of Acts	05
8.	Opportunity for Public Comment	06
*	Statement of Purpose	06
9.	Special Orders of the Day	06
	A. Presentation of Pharmacist Gold Certificates	06
	B. Presentation of Distinguished Service Award	06
10.	Committee Reports	
	A. Finance	07
	B. Application Review	07
	C. Reciprocity	07
	D. Violations	80
	E. Impairment	10
	F. Reinstatement	12
	G. Tripartite	12
	H. Regulation Revision	13
	I. Executive	16
11.	Staff Reports	
	J. Assistant Executive Director	20
	K. General Counsel	21
	L. Executive Director	22
12.	Technology Presentation re Real-Time Benefit Check	
	Ms. Kim Diehl-Boyd, CoverMyMeds	07
13.	New Agenda Items Added During Meeting	
	A. Regulatory Project 2019-1A ~ Marijuana Pharmacies	23
14.	Announcements	23
15.	Recess	24

Agenda Iten	n No. <u>Description</u>	Page No.
Thursday, M	<u> May 30, 2019</u>	
A.	Call to Order	24
B.	Invocation & Pledge of Allegiance	24
C.	Quorum Call	24
D.	Call for Additional Agenda Items & Adoption of Agenda	24
E.	Opportunity for Public Comment	24
*	Appearances	24
F.	Formal Hearings	25
G.	Report of Violations Committee	27
H.	Report of General Counsel	28
l.	Adjourn	28

A regular meeting of the Louisiana Board of Pharmacy was held on Wednesday, May 29, 2019 at the office of the Louisiana Board of Pharmacy, located at 3388 Brentwood Drive in Baton Rouge, Louisiana 70809-1700. The meeting was held pursuant to public notice, each member received notice, and public notice was properly posted.

## 1. Call to Order

Mr. Carl Aron, President, called the meeting to order at 1:00 p.m.

## 2. Invocation & Pledge

Mr. Aron called upon Mr. Rhonny Valentine for the invocation. Ms. Diane Milano then led the group in the Pledge of Allegiance.

### 3. Quorum Call

Mr. Aron called upon the Secretary, Mr. Richard M. Indovina, Jr., to call the roll to establish a quorum.

### **Members Present:**

Mr. Carl W. Aron

Mr. Allen W. Cassidy, Jr.

Ms. Jacqueline L. Hall

Mr. Richard M. Indovina, Jr.

Mr. Kevin LaGrange

Mr. Robert C. LeBas

Mr. Richard Mannino

Mr. Marty R. McKay

Ms. Diane G. Milano

Mr. Ronald E. Moore

Mr. Don L. Resweber

Mr. Douglas E. Robichaux

Mr. Richard A. Soileau

Dr. Raymond J. Strong

Mr. Rhonny K. Valentine

#### **Member Absent:**

Dr. J. Robert Cloud

Mr. Blake P. Pitre

### **Staff Present:**

Mr. Malcolm J. Broussard, Executive Director

Mr. Carlos M. Finalet, III, General Counsel

Mr. M. Joseph Fontenot, Assistant Executive Director

Mr. Benjamin S. Whaley, Chief Compliance Officer

Ms. Alicia P. Harris, Pharmacist Compliance Officer

Ms. Becky C. Parker, Pharmacist Compliance Officer

Mr. Huey J. Savoie, Pharmacist Compliance Officer

## **Guests:**

Mr. Alfred Gaudet - Gold Certificate Recipient

Ms. Kathleen Gaudet – Gold Certificate Recipient

Mr. William Stroud, III - Gold Certificate Recipient

Ms. Barbara LeBeouf – Gold Certificate Recipient

Mr. Roland Thibodeaux – Gold Certificate Recipient

Mr. Bevan Callicott – Cardinal Health

Mr. Ben J. Sims – Brookshire Grocery Co.

Dr. Alexandre Raymond – Ochsner Medical Center

Ms. Kim Diehl-Boyd – CoverMyMeds

Dr. Gena Territo-Tynes – Ochsner Medical Center

Ms. Patricea Angelle – International Academy of Compounding Pharmacists

Mr. Indovina certified Dr. Cloud and Mr. Pitre were absent; however, the remaining 15 members were present, constituting a quorum for the conduct of official business.

## 4. Call for Additional Agenda Items & Adoption of Agenda

Mr. Aron asked if there were any additional agenda items to be added. Mr. Indovina noted the public hearing for *Regulatory Project 2019-1A* ~ *Marijuana Pharmacies* was held earlier that day, that no comments were received, and that it would be appropriate to determine whether to continue the promulgation process that day instead of waiting until the next Board meeting in November. He moved to amend the agenda to add the regulatory project. There were no member questions or public comment. The motion was adopted following a unanimous roll call vote in the affirmative. Mr. Aron added the regulatory project to the agenda, noting the Item Number as 13-A. With no further requests to amend the agenda, and without objection, the members adopted the posted agenda dated May 13, 2019, as amended. Mr. Aron requested authority to re-order the agenda as may become necessary, and there were no objections to that request.

#### 5. Consideration of Minutes

Mr. Aron reminded the members they had received the draft minutes from the Regular Board Meeting held on February 19, 2019 in Monroe, Louisiana. With no objections, he waived the reading of the draft minutes. With no requests for amendment or any objection to their approval, Mr. Aron declared the minutes were approved as presented. Mr. Indovina reminded the members to sign the Minute Book.

## 6. Report on Action Items

Mr. Aron called on Mr. Broussard for the report. Mr. Broussard directed the members to a copy of the report in their meeting binder. There were no questions from the members or guests.

### 7. Confirmation of Acts

Pursuant to Mr. Aron's declaration that the officers, committees, and executive director had attended to the business of the Board since their last meeting in accordance with policies and procedures previously approved by the Board, Mr. Moore moved,

**Resolved**, that the actions taken and decisions made by the Board officers, Board committees, and Executive Director in the general conduct

and transactions of Board business since February 19, 2019 are approved, adopted, and ratified by the entire Board.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

## 8. Opportunity for Public Comment

Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present, and none were offered.

## \* Statement of Purpose

Mr. Aron reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their legislative mandate in mind as they considered all the matters before them.

## 9. Special Orders of the Day

## A. Presentation of Pharmacist Gold Certificates

Mr. Aron reminded the members and guests of the Board's award of a Pharmacist Gold Certificate to a pharmacist completing 50 years of Louisiana pharmacist licensure. He informed the audience the Board issued new licenses to 173 pharmacists in 1969, and of that number the licenses of 50 pharmacists were still in active status. He noted five of those pharmacists were present and had requested to receive their certificates during the Board meeting. Mr. Aron then presented Gold Certificates to the following pharmacists, noting during each presentation a synopsis of the recipient's professional service:

PST.009300 - William Fletcher Stroud, III

PST.009422 – Alfred Louis Gaudet

PST.009438 - Barbara Ann LeBeouf

PST.009544 - Roland James Thibodeaux

PST.009633 - Kathleen Vocke Gaudet

The members and guests congratulated each of the recipients with standing ovations.

## B. Presentation of Distinguished Service Award

Mr. Aron noted one of the members was nearing the completion of a six year term of service on the Board. He reminded the members and guests that Governor Bobby Jindal had appointed Ms. Diane Milano to the Board on July 1, 2013 and that her term would expire on June 30, 2019. During his presentation of the Distinguished Service Award to Ms. Milano, he noted her service on various Board committees and faithful participation in Board meetings and administrative hearings. Ms. Milano expressed her appreciation for the award and indicated her hope for continued service through another appointment. The members and guests congratulated her with a generous round of applause.

At this point, Mr. Aron re-ordered the agenda to accommodate a presenter with flight arrangements later that afternoon.

## 12. Technology Presentation re Real-Time Benefit Check – Ms. Kim Diehl-Boyd, CoverMvMeds.

Mr. Aron invited Ms. Diehl-Boyd to the witness table to introduce herself and make her presentation to the members. She directed the members to a copy of her presentation in their electronic meeting binder. She then gave a brief introduction to the company before describing a technology service which allows a prescriber to ascertain a patient's third party insurance coverage of a medication intended to be prescribed. The service allows the prescriber and the patient to know the approximate price of the medication for the patient at the pharmacy of the patient's choice prior to the patient leaving the prescriber's office. The members asked several questions about different aspects of the service. Ms. Diehl-Boyd promised to follow-up after the meeting with information about a question relative to cash prices at pharmacies. Mr. Aron expressed his appreciation for her presentation.

At this point, Mr. Aron recognized Ms. Alicia Harris, a pharmacist compliance officer who recently affiliated with the Board and was not present at the previous Board meeting. He introduced her to the members, confirmed her territory, and welcomed her to the Board's staff.

Mr. Aron then returned to the sequence of the posted agenda.

## 10. Committee Reports

### A. Finance Committee

In the absence of Mr. Blake Pitre, Chair of the Finance Committee, Mr. Aron called upon the ranking member, Mr. Marty McKay, for the committee report. Mr. McKay directed the members to the *Interim Report for Fiscal Year 2018-2019* in their meeting binder. Mr. McKay summarized the report for the members; there were no questions. He reminded the members no action was necessary for that report.

Finally, Mr. McKay closed his report with appreciation to the other committee members for their ongoing efforts.

## B. Application Review Committee

Mr. Aron called upon Mr. Soileau for the committee report. Mr. Soileau reported the committee had not met since the previous Board meeting.

Finally, Mr. Soileau closed his report with appreciation to the other committee members for their ongoing efforts.

## C. Reciprocity Committee

Mr. Aron called upon Mr. Cassidy for the committee report. He reported the staff had evaluated 86 applications for pharmacist licensure by reciprocity since the last Board meeting and that none of them contained information that warranted a committee level review. In conformance with policies and procedures previously approved by the Board, the staff approved the

applications and issued the credentials.

Finally, he closed his report with appreciation to the other committee members for their ongoing efforts.

## D. Violations Committee

Mr. Aron called upon Mr. Indovina for the committee report. Mr. Indovina reported the committee held preliminary hearings on March 20-21, 2019 to consider their posted agenda which included 22 cases: eight pharmacists, six pharmacy technicians, one pharmacy technician candidate, and seven pharmacy permits. Two respondents failed to appear; the committee voted to refer both of them for formal administrative hearings which were held the following day. After interviews and deliberations at the preliminary hearings, the committee continued one case for further investigation; voted to take no action against another respondent; voted to allow one respondent to enter into a private no-practice agreement while that case is continued; and also voted to issue non-disciplinary Letters of Noncompliance to two respondents. The committee then voted to offer proposed voluntary consent agreements to the remaining 15 respondents. Of that number, 12 accepted their proposed consent agreements; the other three were scheduled for a future administrative hearing. He then reported the receipt of a signed consent agreement from a respondent who case had been previously continued. Mr. Indovina then presented the following proposed consent agreements to the members for their consideration.

Ja'Faira Romeshia Lajoy Holland (CPT.013935): Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$250 plus administrative costs.

**Destiny Araine Woolfolk (CPT.010453):** Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the certificate for one year and stayed the execution of the suspension, then placed the certificate on probation for one year effective May 29, 2019 subject to certain terms enumerated within the consent agreement, and further, assessed administrative costs.

Racheal Jordan Flores (PST.021687): Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Warning, and further, assessed administrative and investigative costs.

Walgreen La. Co., Inc. d/b/a Walgreen Pharmacy No. 110-02995 [Baton Rouge, LA] (PHY.002868): Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public

comments. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$10,000 plus administrative and investigative costs.

Prescription Dispensing Laboratories, Inc. *d/b/a* Prescription Dispensing Laboratories [Cedar Park, TX] (PHY.007538): Mr. Indovina moved to approve the proposed voluntary consent agreement. Mr. Finalet responded to a question from one member; there were no public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$5,000 plus administrative costs.

Noah's Pharmacy, LLC d/b/a Noah's Pharmacy [Brusly, LA] (PHY.006145 ~ Case No. 18-0364): Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board terminated the previously imposed probationary period, suspended the permit for five years and stayed the execution of the suspension, then placed the permit on probation for five years effective May 29, 2019 subject to certain terms enumerated within the consent agreement, and further, assessed administrative and investigative costs.

**Gaylyn Elizabeth Bellaire (PST.014692):** Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board restricted the license by prohibiting the acceptance of an appointment as the pharmacist-in-charge of any pharmacy until after May 29, 2020, and further, assessed a fine of \$500 plus administrative costs.

Kimberly Juanita Murphy (PST.016122): Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board terminated the previously imposed probationary period, suspended the license for five years and stayed the execution of the suspension, then placed the license on probation for five years effective May 29, 2019 subject to certain terms enumerated within the consent agreement, and further, assessed a fine of \$7,500 plus administrative costs.

Noah's Pharmacy, LLC d/b/a Noah's Pharmacy [Brusly, LA] (PHY.006145 ~ Case No. 19-0024): Mr. Indovina moved to approve the proposed voluntary consent agreement. He replied to questions from six members; there were no public comments. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$5,000 plus administrative and investigative costs.

Lato Drug Company, Inc. d/b/a Post Haste Pharmacy [Hollywood, FL] (PHY.006650): Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$15,000 plus administrative and investigative costs.

Winn Dixie Stores, Inc. d/b/a Pathstone Health Services [Jacksonville, FL] (PHY.007203): Mr. Indovina moved to approve the proposed voluntary consent agreement. He replied to questions from three members; there were no public comments. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$12,500 plus administrative and investigative costs.

Leslie Dominique Threatts (CPT.014040): Mr. Indovina moved to accept the voluntary surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the credential, resulting in the active suspension of the certificate for an indefinite period of time effective March 21, 2019.

**Thomas Joseph Walker (PST.015721):** Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further assessed a fine of \$1,000 plus administrative and investigative costs.

Mr. Indovina then presented the Complaint Investigation Monitor Report, which demonstrated the opening of 384 new cases and the closure of 349 cases during the current fiscal year. The average number days for staff to complete their case investigation was 51 days. Of the 349 case closures, 15 of them [4.3%] exceeded the policy goal of 180 days for completion of case investigations.

Mr. Indovina reported the committee was scheduled to meet on June 11-12 to consider the 24 cases on that docket, which includes 10 pharmacists, seven pharmacy technicians, one pharmacy technician candidate, five pharmacy permits and one DME permit.

Finally, he concluded his report with appreciation to the other committee members for their ongoing efforts and to the compliance officers for the quality of their case investigations.

### E. Impairment Committee

Mr. Aron called upon Ms. Hall for the committee report. Ms. Hall reported the committee met the previous day to consider four referrals from the staff – two applications for reinstatement of credentials, one appearance for informal conference, and one appearance for guidance. The committee also performed their annual review of the roster of approved addictionists. Following their interviews of the applicants and subsequent deliberations, the

committee developed recommendations for the applicants. Ms. Hall then presented the following files to the members for their consideration.

Michael Wayne Lindsey (PST.015624) Ms. Hall moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted the applicant's request for reinstatement of the previously suspended license contingent upon the completion of certain requirements identified within the consent agreement, to suspend the newly-reinstated license for 15 years and stay the execution of the suspension, and then place the license on probation for 15 years effective on the date of reinstatement subject to certain terms enumerated within the consent agreement.

Steve Khai Vu (PST.015586) Ms. Hall moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted the applicant's request for reinstatement of the previously suspended license contingent upon the satisfaction of certain requirements identified within the consent agreement, to suspend the newly-reinstated license for five years and stay the execution of the suspension, then place the license on probation for five years effective on the date of reinstatement subject to certain terms enumerated within the consent agreement.

**Todd Michael Durham (PST.016962)** Ms. Hall moved to accept the voluntary surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the credential, resulting in the active suspension of the license for an indefinite period of time effective May 28, 2019.

David Evans Collins (PST.014181) Ms. Hall moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted the request for reinstatement of the previously suspended license, converted the duration of the suspensive period from an indefinite term to a term of 15 years and stayed the execution of the suspension, then placed the license on probation for 15 years effective May 29, 2019 subject to certain terms enumerated within the consent agreement.

Ms. Hall reported the committee had performed its annual review of the roster of approved addictionists, offered no proposed revisions, and voted to recommend the Board's continuing approval of the current roster. On behalf of the committee, Ms. Hall then moved,

**Resolved**, to continue the approval of the current <u>Roster of</u>

## Approved Addictionists.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

Finally, Ms. Hall closed her report with appreciation to her fellow committee members for their work the previous day.

### F. Reinstatement Committee

Mr. Aron called upon Mr. Moore for the committee report. Mr. Moore reported the committee had met the previous day to consider three referrals from the staff. Following their interviews of the applicants and subsequent deliberations, the committee developed recommendations for the applicants. Mr. Moore then presented the following files to the members for their consideration.

Bocage Pharmacy Centre, Inc. d/b/a Bocage Pharmacy Centre (CDS.039257-PHY): Mr. Moore moved to reinstate the previously suspended CDS license without restriction. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted the applicant's request for reinstatement of the previously suspended license and then restored the CDS license to active and unrestricted status.

Virginia Kay Alexander (CPT.006750): Mr. Moore moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted the request for reinstatement of the lapsed certificate contingent upon the satisfaction of certain requirements identified within the consent agreement.

Alicia Williams Lafayette (CPT.006921): Mr. Moore moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted the applicant's request for reinstatement of the lapsed certificate contingent upon the satisfaction of certain requirements identified within the consent agreement.

Mr. Moore closed his report with appreciation to the other committee members for their work the previous day.

## G. Tripartite Committee

Mr. Aron called upon Mr. Resweber for the committee report. Mr. Resweber reported the committee had not met since the previous Board meeting.

At this point, Mr. Aron declared a recess. It was noted the members recessed at 2:40 p.m. and then reconvened at 3:05 p.m. Mr. Aron resumed the sequence of the posted agenda.

## H. Regulation Revision Committee

Mr. Aron called upon Mr. McKay for the committee report. Mr. McKay reported the committee met on April 24, 2019 to consider the items on their posted agenda. During that meeting, the committee voted to recommend the approval of four regulatory proposals. He then presented the following proposals to the Board for their consideration.

## Regulatory Proposal 2018-B ~ Drug Disposal by Pharmacies (Draft #5)

Mr. McKay informed the members of the committee's deliberations on whether and how a pharmacy could facilitate the disposal of previously dispensed prescription drugs no longer needed or wanted by consumers.

- ➤ The committee considered whether a pharmacy should accept drug returns from consumers for destruction. They received stakeholder input concerning the potential for diversion within a pharmacy, both for theft as well as return to return to active dispensing stock. They determined it appropriate to allow a pharmacy to accept returns and imposed a quarantine and security requirement in the proposed rule.
- ➤ The committee considered whether a pharmacy should be required to accept drug returns for prescriptions it dispensed and permitted to accept drugs dispensed by other pharmacies. The committee declined to require pharmacies to accept any drug returns, but determined it appropriate to require pharmacies to inform consumers of their disposal options.
- With respect to pharmacies electing to accept drugs for disposal, the committee reviewed existing federal standards for the disposal of certain types of drugs and inserted a requirement to comply with those federal standards.

Mr. McKay noted the regulatory proposal inserts the proposed changes into three different chapters – Chapter 15 for hospital pharmacies, Chapter 25 for all pharmacies, and Chapter 27 for controlled substances. On behalf of the committee, Mr. McKay then moved,

**Resolved**, to approve <u>Regulatory Proposal 2018-B ~ Drug</u> <u>Disposal by Pharmacies (Draft #5)</u>, and further, to authorize the Executive Director to promulgate the proposed rule upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

Mr. McKay replied to questions from three members; there were no public comments. The motion was adopted after a unanimous vote in the affirmative.

## Regulatory Proposal 2018-N ~ Pharmacy Compounding (Draft #5)

Following the publication of the final FDA Guidance Document relative to the compounding of copies of commercially available products, the committee was asked to review the Board's rules for pharmacy compounding. The committee recommends amending Subsection F of

Section 2535 which is the Board's rule on pharmacy compounding. The proposal removes the reference to the ASHP website as a source of drugs in shortage, leaving the official FDA website for that information. The proposal also amends the allowance to compound copies of commercially available products with only minor changes to the active ingredient profile using the same language in the FDA Guidance Document. On behalf of the committee, Mr. McKay then moved,

**Resolved**, to approve <u>Regulatory Proposal 2018-N ~ Pharmacy Compounding (Draft #5)</u>, and further, to authorize the Executive Director to promulgate the proposed rule upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions; there was one public comment. The motion was adopted after a unanimous vote in the affirmative.

## Regulatory Proposal 2019-A ~ Pharmacy Records (Draft #3)

Mr. McKay informed the members the proposal originated as a request from long term care pharmacies to implement the provisions of Act 602 of the 2018 Legislature recognizing the use of chart orders. Since chart orders are analogous to prescriptions, the committee's deliberations revealed the necessity to amend several different chapters and sections of the rules. Draft #2 was the result of those deliberations. While preparing that draft for the Board's consideration, staff noted several portions of that draft affected the chapter of rules for automated medication systems, which is the subject of another regulatory proposal still under consideration by the committee. Draft #3 is the result of the removal of the portion of Draft #2 relative to automated medication system. That portion of Draft #2 was transferred to a different regulatory proposal relative to automated medication systems still under review by the committee. Mr. McKay also noted that while the proposal contains suggested revisions to pharmacy record rules to include chart orders, it also includes a large number of technical amendments necessary to conform the Board's rules to the style required by the state register. On behalf of the committee, Mr. McKay then moved,

**Resolved**, to approve <u>Regulatory Proposal 2019-A ~ Pharmacy</u> <u>Records (Draft #3)</u>, and further, to authorize the Executive Director to promulgate the proposed rule upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were comments from two members and no public comments. The motion was adopted after a unanimous vote in the affirmative.

## Regulatory Proposal 2019-D ~ Pharmacist Access to PMP (Draft #1)

Mr. McKay reminded the members of the legislative mandate to automatically register all prescribers to grant them access to the state prescription monitoring program database. The committee reviewed the current law and rule to determine whether such automatic registration could also be offered to pharmacists. Staff determined no statutory amendment was necessary and that such capacity could be accomplished with a change in the rule. The proposal amends registration procedures in the PMP rules. On behalf of the committee, Mr. McKay then moved,

**Resolved**, to approve <u>Regulatory Proposal 2019-D ~ Pharmacist</u> <u>Access to PMP (Draft #1)</u>, and further, to authorize the Executive Director to promulgate the proposed rule upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

Mr. McKay reported on other topics assigned to the committee.

- With respect to the committee agenda item relative to automated medication systems, the committee requested additional revisions and an updated draft for the next committee meeting.
- With respect to the committee agenda item relative to the planned new <u>USP <800> Hazardous Drugs ~ Handling in Healthcare Settings</u>, the USP-800 Subcommittee held their first meeting on April 23. They planned their approach to developing a recommendation for the Regulation Revision Committee and are actively working to develop a document for consideration during their next meeting on June 12. During the April 24 meeting of the full committee, the members determined it appropriate to suggest a delay in the Board's enforcement of the new USP <800>. On behalf of the committee, Mr. McKay then moved,

**Resolved**, that the Board delay the enforcement of the provisions of <u>USP <800> Hazardous Drugs ~ Handling in Healthcare Settings</u> until January 1, 2021.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- ➤ With respect to the committee agenda item relative to petitions for the return of inactive pharmacist licenses to active status, the committee reviewed the current rule in Section 505 and determined an interpretation of that rule via a policy document would be sufficient to achieve the desired outcome. The committee communicated that recommendation to the Executive Committee, which had prepared a proposed policy document for the Board's consideration later during that meeting. The Regulation Revision Committee returned their assignment to the Board with no further action.
- ➤ With respect to the committee agenda item relative to compounding in nuclear pharmacies, the committee is aware of the September 2018 final guidance document from the FDA on that topic as well as the anticipated new USP <825> Radiopharmaceuticals chapter. The committee is anticipating the appointment of a USP-825 Subcommittee and requested nominations of interested and qualified pharmacists by the members.

➤ With respect to the committee agenda item relative to pharmacy technician training programs, the committee members reviewed the current rule and then voted to return the item to the Board with no recommendation. There was substantial discussion but no further guidance or direction to the committee.

Finally, Mr. McKay closed his report by identifying the public members of the USP-800 Subcommittee:

- ➤ Ms. Patricea Angelle, from Prescription Compounds in Baton Rouge;
- ➤ Ms. Susan Caudle, from Line Avenue Pharmacy in Shreveport;
- ➤ Ms. Angelle Huff, from The Wellness Corner in Prairieville;
- > Dr. Gary LeBlanc, from Heart Hospital in Lafayette; and
- ➤ Dr. Heather Maturin, from Ochsner Medical Center in Baton Rouge.

Mr. McKay expressed his appreciation to those pharmacists as well as the committee members for their ongoing efforts.

### I. Executive Committee

Mr. Aron reported the committee had met the previous day to consider the items on their posted agenda. He indicated Mr. McKay was prepared to offer motions on behalf of the committee.

## <u>Proposed Revision of PPM.I.C.5.a ~ Reinstatement Committee – Case</u> Management

Mr. Aron reported the Regulation Revision Committee had suggested an interpretation of Section 505 of the Board's rule relative to the process for returning a pharmacist license on inactive status to active status in lieu of a revision of the rule. The committee reviewed the existing policy of the Reinstatement Committee and determined a revision of that policy describing a process for such petitions would be appropriate. On behalf of the committee, Mr. McKay moved,

**Resolved**, to approve the proposed revision of *PPM.I.C.5.a* ~ *Reinstatement Committee* – *Case Management* for the Board's *Policy & Procedure Manual.* 

Mr. Aron replied to questions from two members; there were no public comments. The motion was adopted after a unanimous vote in the affirmative.

## Proposed Revision of Pharmacy Inspection Blueprints

Mr. Aron reminded the members of their adoption of the national blueprints for pharmacy inspections in August 2017. He reminded them there were four modules: basic pharmacy services, compounding of nonsterile preparations, compounding of sterile preparations, and nuclear pharmacy services. He informed the members there had been some minor updates to the first three of those blueprints and that it was necessary to update those blueprints in the Board's *Policy & Procedure Manual*. On behalf of the committee, Mr. McKay moved,

**Resolved**, to approve the proposed revision of *PPM.IV.B.2.d* ~

Inspection of Basic Pharmacy Services for the Board's <u>Policy &</u> Procedure Manual.

Mr. Aron replied to questions from multiple members; there was one public comment. The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

**Resolved**, to approve the proposed revision of *PPM.IV.B.2.e* ~ *Inspection of Nonsterile Compounding Services* for the Board's *Policy & Procedure Manual.* 

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

**Resolve**d, to approve the proposed revision of *PPM.IV.B.2.f* ~ *Inspection of Sterile Compounding Services* for the Board's *Policy* & *Procedure Manual.* 

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

## <u>Proposed New Policy PPM.III.B.03 ~ Application for New Pharmacy Intern</u> Registration

<u>Proposed New Policy PPM.III.B.03.a ~ Maintenance of Pharmacy Intern</u> Registration

Mr. Aron reported the recent inquiry from a college of pharmacy as to the impact of a pharmacy intern taking a leave of absence on his eligibility to retain his pharmacy intern registration. Although the Board has consistently allowed an intern to be out of school for up to one semester and retain the registration, the Board does not have a formal policy. He requested staff develop policies reflecting current practice, and the committee voted to recommend their approval. On behalf of the committee, Mr. McKay moved,

**Resolved**, to approve *PPM.III.B.03* ~ *Application for New Pharmacy Intern Registration* and *PPM.III.B.03.a* ~ *Maintenance of Pharmacy Intern Registration* for the Board's *Policy & Procedure Manual*.

Mr. Aron replied to a question from one member; there were no public comments. The motion was adopted after a unanimous vote in the affirmative.

## Continuing Approval of Updated Policy & Procedure Manual

Mr. Aron reminded the members of the changes they had made to the manual since their last annual review in May 2018. The committee recommended the continuing approval of the updated manual. On behalf of the committee, Mr. McKay moved,

**Resolved**, to continue the approval of the Board's updated *Policy* & *Procedure Manual*.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

### Proposed New Policy LPM.I.R ~ Confined Spaces

Mr. Aron reported the Division of Administration's Office of Risk Management

suggested the implementation of a new policy relative to confined spaces. The committee voted to recommend its approval. On behalf of the committee, Mr. McKay moved,

**Resolved**, to approve the proposed new policy *LPM.I.R* ~ *Confined Spaces* for the Board's *Loss Prevention Manual*.

Mr. Aron replied to questions from two members; there were no public comments. The motion was adopted after a unanimous vote in the affirmative.

## Continuing Approval of Updated Loss Prevention Manual

Mr. Aron reported the only change to the manual since the last annual review in May 2018 was the policy just approved. The committee recommended the continuing approval of the updated manual. On behalf of the committee, Mr. McKay moved,

**Resolved**, to continue the approval of the Board's updated <u>Loss</u> *Prevention Manual*.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

## Annual Review of Roster of Approved Colleges of Pharmacy

Mr. Aron reminded the members the only changes to the roster since their last annual review in May 2018 was the addition of one new school in August 2018 and the removal of probationary status for two schools at the same time. The committee recommended the continuing approval of the updated roster. On behalf of the committee, Mr. McKay moved,

**Resolved**, to continue the approval of the Board's <u>Roster of</u> Approved Colleges of Pharmacy.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

# <u>Annual Review of Roster of Approved Pharmacy Technician Training Programs</u>

Mr. Aron reminded the members the only change to the roster since their last annual review in May 2018 was the addition of one new program in November 2018 and the removal of three programs in February 2019. Since that meeting, the Board had received a request for approval from two programs. The committee recommended the approval of both new programs as well as the continuing approval of the updated roster. On behalf of the committee, Mr. McKay moved,

**Resolved**, to approve the request from Health Mart Systems for recognition as an approved pharmacy technician training program.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

**Resolved**, to approve the request from American National University for recognition as an approved pharmacy technician training program.

There were no member questions or public comments. The motion was

adopted after a unanimous vote in the affirmative. Mr. McKay then moved, **Resolved**, to continue the approval of the Board's updated <u>Roster</u> of Approved Pharmacy Technician Training Programs.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

## Annual Legislative Financial Audit

Mr. Aron reminded the members of the upcoming annual financial audit and of the necessity to approve the management representation letter. The committee reviewed the proposed letter and recommended its approval. On behalf of the committee, Mr. McKay moved,

**Resolved**, to approve the <u>Management Representation Letter for</u> the 2019 Financial Audit.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

# <u>Interim Procurement for Louisiana Medical Marijuana Tracking System</u> (LMMTS)

Mr. Aron reminded the members of the tracking system established for the medical marijuana products. The system contracted for by the state agriculture department did not include a method to uniquely identify marijuana products. Marijuana pharmacies require a unique number for such products to facilitate the reporting of the dispensing transactions to the state prescription monitoring program. Mr. Aron directed staff to work with the vendor for LMMTS to establish a method to assign product identification numbers to the marijuana products to be sold by the producers to the pharmacies. The vendor offered a module of their system which had not been requested by the state agriculture department. So as to not interrupt the progress of the implementation of the statewide program, Mr. Aron authorized the interim procurement of the product identification module which will integrate with the remainder of the tracking system. However, in order to continue the purchase of the module in the next fiscal year, Board approval was necessary. The committee reviewed the procurement and recommended the approval of the purchase for the following fiscal year. On behalf of the committee, Mr. McKay moved,

**Resolved**, to approve the proposed agreement with Metrc for the product identification module in the Louisiana Medical Marijuana Tracking System, at the stipulated rate, in an amount not to exceed \$20,000 for Fiscal Year 2019-2020.

Several members questioned how the module would integrate with the pharmacy information systems and facilitate the reporting of dispensing transactions to the state prescription monitoring program. Some of the members questioned the necessity of the program. Some of the members understood the necessity of the interim procurement and questioned whether it would be necessary every year. Some of the members questioned whether the state agriculture department should include that module in the annual renewal of their contract for the tracking system going forward. There were

no public comments. The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Aron closed his report with appreciation for the other committee members and their work the previous day.

At this point, Mr. Aron declared a brief recess. It was noted the members recessed at 5:20 p.m. and then reconvened at 5:30 p.m. Mr. Aron resumed the sequence of the posted agenda.

## 11. Staff Reports

J. Report of Assistant Executive Director

Mr. Aron called upon Mr. Fontenot for the report. He directed the members to the quarterly report of the prescription monitoring program, detailing the prescription transaction counts as well as queries from prescribers, dispensers, and law enforcement agencies. He answered questions from several members.

Mr. Fontenot then directed the members to the requests from 28 pharmacies seeking a waiver from the duty to report zero prescription transaction reports to the prescription monitoring program. Mr. McKay then moved,

**Resolved**, to authorize the issuance of full PMP reporting waivers to:

```
> PHY.007227-NR - A-1 Pharmacy Services (MS);
```

<sup>&</sup>gt; PHY.007532-NR - Allivet (FL);

<sup>&</sup>gt; PHY.007298-NR - Benzer Pharmacy (FL);

<sup>&</sup>gt; PHY.007727-NR - Bio Tek reMEDys (DE);

<sup>&</sup>gt; PHY.005543-NR - Clinical Solutions (TN);

<sup>&</sup>gt; PHY.007828-NR - Concentrix CVG Corporation (AZ);

<sup>&</sup>gt; PHY.006342-NR - Coram CVS/Specialty Infusion Services (MN);

<sup>&</sup>gt; PHY.006242-NR - Exactus Pharmacy Solutions (FL);

<sup>&</sup>gt; PHY.000381-HOS - Franklin Foundation Hospital Pharmacy (LA)

<sup>&</sup>gt; PHY.006340-HOS - Franklin Medical Center Pharmacy (LA);

<sup>&</sup>gt; PHY.007826-NR - GoLiveWell Pharmacy (MO);

<sup>&</sup>gt; PHY.007723-NR - Haltom Pharmacy (TX);

<sup>&</sup>gt; PHY.006754-NR - Hometech Advanced Therapies (PA);

<sup>&</sup>gt; PHY.000501-HOS – Iberia Medical Center Pharmacy (LA);

<sup>&</sup>gt; PHY.007286-SAT – Iberia Medical Center North (LA);

<sup>&</sup>gt; PHY.000471-HOS - Hood Memorial Hospital Pharmacy (LA);

<sup>&</sup>gt; PHY.007885-NR - Kroger Specialty Infusion Therapy (TX);

<sup>&</sup>gt; PHY.007881-NR - Lemonaid Pharmacy (MO);

<sup>&</sup>gt; PHY.007842-NR – MediStar Healthcare Connections (AZ);

<sup>&</sup>gt; PHY.007896-NR - Milton Medical & Drug Co. (FL);

<sup>&</sup>gt; PHY.007872-NRN - NuTech (TX);

<sup>&</sup>gt; PHY.007879-HOS - Ochsner LSU Health Shreveport (LA):

<sup>&</sup>gt; PHY.007877-HOS – Our Lady of Lourdes Women's & Children's Hospital Pharmacy (LA);

- > PHY.007888-HOS Our Lady of the Lake Ascension Hospital Pharmacy (LA):
- > PHY.007860-NR Pinnacle Medical Solutions (MS);
- > PHY.007870-NR Skip's Pharmacy (FL);
- > PHY.007857-NR Soleo Health (IL); and
- > PHY.007807-NR Unlimited Pharmacy (TX) once they have executed the standard consent agreement for that purpose.

Mr. Fontenot replied to questions from two members. There were no public comments. The motion was adopted after a unanimous vote in the affirmative.

He then reported on the progress of the program's collaboration with the Dept. of Health to integrate the PMP into all the electronic health record systems and pharmacy information systems in the state. He noted the grant funding supporting that initiative required completion of the integration by June 30, 2019.

Finally, Mr. Fontenot indicated completion of his report.

## K. Report of General Counsel

Mr. Aron called upon Mr. Finalet for the report. Mr. Finalet reported the May 20, 2019 decision of the 19<sup>th</sup> Judicial District Court in *Rx Greenhouse*, *LLC*, *et al vs The Louisiana Board of Pharmacy*. The judge affirmed the Board's decision in its award of the marijuana pharmacy permit for Region 1. Mr. Finalet then presented the following proposed voluntary consent agreements to the members for their consideration.

Randolph Adam Baez (PST.018669): Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$1,000 plus administrative costs.

Pharmcore, Inc. d/b/a Hallandale Pharmacy [Fort Lauderdale, FL] (PHY.00.7866): Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$10,000 plus administrative costs.

Robert Brent Clevenger (PST.021999): Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for four years plus nine months plus twenty days and stayed the execution of the suspension, then placed the license on probation for four years plus nine months plus twenty days effective May 29, 2019 and terminating March 21, 2024 subject to certain terms enumerated within the consent agreement, and further, assessed administrative costs. The Board took note the probationary period

was scheduled to proceed concurrently with the probationary period imposed by the Alabama Board of Pharmacy on his Alabama pharmacist license.

**Nguyet Anh Thi Nguyen (CPT.006154):** Mr. McKay moved to accept the voluntary surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the credential, resulting in the active suspension of the certificate for an indefinite period of time effective April 22, 2019.

Pharmaceutical Specialties, Inc. d/b/a Hoye's Pharmacy [Tampa, FL] (PHY.007496): Mr. Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$5,000 plus administrative costs.

Whitney Nicole Cantrelle (PST.021219): Mr. McKay moved to accept the voluntary surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the credential, resulting in the active suspension of the license for an indefinite period of time effective April 29, 2019.

**Tanya Centrell Ann Ventress (CPT.004921):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$250 plus administrative costs.

**Brandee Cecilia Lam (PST.021000):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$1,000 plus administrative costs.

Finally, Mr. Finalet indicated the completion of his report.

## L. Report of Executive Director

Mr. Aron called upon Mr. Broussard for the report. Mr. Broussard directed the members to his report in the meeting binder. He reviewed the following topics:

- Meeting Activity
- Reports
  - Internal Reports
     Credentials Division
     Census Report
     Licensure Activity Report

**Application Activity Report** 

**Exceptions Report** 

**Compliance Division** 

Census Report

Complaint Investigation Policy Monitor

External Reports

Administrative and Legislative Agency Reports

Examinations

**MPJE** 

**NAPLEX** 

**ExCPT** 

**PTCB** 

Operations

Credentials Division

Compliance Division

Administrative Division

State Activities

La. Legislature

La. State Board of Medical Examiners

Regional & National Activities

National Association of Boards of Pharmacy (NABP)

NABP-AACP District 6

**MALTAGON** 

International Activities

International Pharmaceutical Federation (FIP) dotPharmacy Verified Websites Program

Finally, Mr. Broussard indicated the completion of his report.

## 13. New Agenda Items Added During Meeting

## A. Regulatory Project 2019-1A ~ Marijuana Pharmacies

Mr. Aron reminded the members of the public hearing earlier that day to receive comments and testimony on the proposed rule. The Board received no comments or testimony either prior to or during the public hearing. He questioned whether they wished to entertain any amendments to the proposed rules. With no requests for any further amendments. Mr. McKay then moved,

**Resolved**, to make no revisions to the original proposed rule and to direct staff to submit the required reports and continue the promulgation process.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

## 14. Announcements

Mr. Aron directed the members to the announcements in their meeting binder. He announced the next meeting of the board would be held on August 14 at the Board office in Baton Rouge.

### 15. Recess

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board and without objection, Mr. Aron recessed the meeting at 5:45 p.m.

\* \*

An Administrative Hearing was convened on Thursday, May 30, 2019 in the Boardroom of the Board's office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The hearing was held pursuant to public notice, each member received notice, each respondent received notice (unless specifically stated otherwise in the official transcript), and public notice was properly posted.

### A. Call to Order

Mr. Aron called the hearing to order at 8:35 a.m.

## B. Invocation & Pledge

Mr. Aron called upon Mr. Valentine for the invocation. Dr. Strong then led the group in the Pledge of Allegiance.

### C. Quorum Call

Mr. Aron called upon Secretary Indovina and he called the roll. After doing so, he certified Dr. Cloud, Mr. Mannino, Mr. Moore, and Mr. Pitre were absent; however, the remaining 13 members were present, constituting a quorum for the conduct of official business.

## D. Call for Additional Agenda Items & Adoption of Agenda

Mr. Aron asked if there were any additional agenda items, and none were requested. With no objection, the Board adopted the posted agenda dated May 20, 2019.

## E. Opportunity for Public Comment

Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and prior to the vote on each agenda item. He solicited general comments on non-agenda items from the guests present, and none were offered.

### *Appearances*

Mr. Aron indicated he would serve as the Hearing Officer. Mr. Carlos Finalet served as the Prosecuting Attorney. Ms. Susan Erkle served as the Official Recorder, and Mr. Malcolm Broussard served as the Hearing Clerk.

Mr. Aron informed the members the cases on the agenda originated with the Violations Committee, and that the members of that committee in attendance at their December 5, 2018 and March 19, 2019 meetings would be recused from the hearings. In particular, Dr. Cloud, Ms. Hall, Mr. Indovina, Mr. Robichaux, and Mr. Valentine were recused. He reminded the other members they should recuse themselves should the need arise.

Without objection, Mr. Aron waived the reading of the posted agenda and instead direction the insertion thereof into these minutes. The posted agenda is recreated here.

### AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official. Revised 05-20-2019

- A. Call to Order
- B. Invocation & Pledge of Allegiance
- C. Quorum Call
- D. Call for Additional Agenda Items & Adoption of Agenda
- E. Opportunity for Public Comment
- \* Appearances
- F. Formal Hearings
  - 1. Case No. 18-0348 ~ CPT.010443 Tiffani Lauren Burnaman
  - 2. Case No. 18-0396 ~ CPT.011436 Christie Elaine Parker
  - 3. Case No. 18-0480 ~ PTC.024692 Jonnesha D'Shae London
- G. Report of Violations Committee Consideration of Proposed Voluntary Consent Agreements
- H. Report of General Counsel Consideration of Proposed Voluntary Consent Agreements & Voluntary Surrenders/Revocations
- I. Adjourn

## F. Formal Hearings

Mr. Finalet informed the hearing panel the second case listed on the agenda would be continued until a future date due to the delayed arrival of a witness affidavit. With Mr. Aron's approval, he then began the hearings by calling the first case listed.

Tiffani Lauren Burnaman (CPT.010443) Mr. Finalet appeared for the Board. The respondent, Tiffani Lauren Burnaman, did not appear and was not represented by counsel. Mr. Aron ruled the hearing would proceed as noticed in the form of a default proceeding. Mr. Finalet offered an opening statement, presented no witnesses and six exhibits, and then proffered proposed Findings of Fact, Conclusions of Law, and Board Order. Mr. Finalet tendered the matter to the hearing panel for its consideration. Mr. Soileau moved to enter into executive session for the purpose of deliberating the disciplinary matter and discussing the respondent's professional competency and fitness for practice. There were no member questions or public comments. The motion was adopted after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered into executive session at 8:45 a.m. and then

reconvened at 8:55 a.m. Mr. Aron returned the hearing panel to open session; he reported no decision was made during the executive session and questioned the members as to their disposition of the case.

Mr. Cassidy then moved,

**Resolved**, that the hearing panel, having heard the testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. Mr. Cassidy then moved,

**Resolved**, that the hearing panel accept the Conclusions of Law as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. Mr. Cassidy then moved,

Resolved, that the hearing panel enter the following order at this time: It is ordered, adjudged, and decreed that Louisiana Pharmacy Technician Certificate No. 10443 held by Tiffani Lauren Burnaman shall be, and is hereby, suspended for an indefinite period of time effective on the entry of this order; and further, the respondent shall pay the following assessments:

- (1) A fine of \$500;
- (2) The administrative hearing fee of \$250; and
- (3) The investigative and hearing costs, including the costs of the prosecuting attorney and the official recorder; and It is further ordered, the acceptance of any future application for the reinstatement of the certificate or any application for any other credential issued by the Board shall be conditioned upon the satisfaction of the following terms:
- (1) Respondent shall have paid all assessments levied herein; and
- (2) Respondent shall have no pending legal or disciplinary matters against her in any jurisdiction.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

Jonnesha D'Shae London (PTC.024692) Mr. Finalet appeared for the Board. The respondent, Jonnesha D'Shae London, did not appear and she was not represented by counsel. Mr. Aron ruled the hearing would proceed as noticed in the form of a default proceeding. Mr. Finalet offered an opening statement, presented one witness and six exhibits, and then proffered proposed Findings of Fact, Conclusions of Law, and Board Order. Mr. Finalet tendered the matter to the hearing panel for its consideration. Mr. Cassidy moved to enter into executive session for the purpose of deliberating the disciplinary matter and discussing the respondent's professional competency and fitness for practice. There were no member questions or public comments. The motion was adopted

after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered into executive session at 9:10 a.m. and then reconvened at 9:15 a.m. Mr. Aron returned the hearing panel to open session; he reported no decision was made during the executive session and questioned the members as to their disposition of the case.

## Dr. Strong then moved,

**Resolved**, that the hearing panel, having heard the testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. Dr. Strong then moved,

**Resolved**, that the hearing panel accept the Conclusions of Law as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. Dr. Strong then moved,

**Resolved**, that the hearing panel enter the following order at this time:

It is ordered, adjudged, and decreed that Louisiana Pharmacy Technician Candidate Registration No. 24692 held by Jonnesha D'Shae London shall be, and is hereby, suspended for an indefinite period of time effective on the entry of this order; and further, the respondent shall pay the following assessments:

- (4) A fine of \$500:
- (5) The administrative hearing fee of \$250; and
- (6) The investigative and hearing costs, including the costs of the prosecuting attorney and the official recorder; and It is further ordered, the acceptance of any future application for the reinstatement of the certificate or any application for any other credential issued by the Board shall be conditioned upon the satisfaction of the following terms:
- (3) Respondent shall have paid all assessments levied herein; and
- (4) Respondent shall have no pending legal or disciplinary matters against her in any jurisdiction.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

Mr. Finalet indicated completion of the cases scheduled for that day. Mr. Aron expressed his appreciation to Ms. Erkle for her recording services that day.

## G. Report of Violations Committee

Mr. Aron noted the committee presented its proposed consent agreement the previous day and there were no additions to that list.

## H. Report of General Counsel

Mr. Aron noted Mr. Finalet presented his proposed consent agreements the previous day and there were no addition to that list.

## I. Adjourn

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron adjourned the hearing at 9:20 a.m.

Respectfully submitted,

\_\_\_\_\_

Richard M. Indovina, Jr. Secretary